Influence of different adjuvant formulations in humoral responses after immunization with a HIV envelope glycoprotein trimer.
Juliana
D.
Apostólico1, 2,
Silvia
B.
Boscardin3,
Márcio
M.
Yamamoto3,
Susan
P.
Ribeiro2, 4,
Rafael
Ribeiro2, 4,
Jorge
Kalil4, 5,
Edécio
Cunha-Neto2, 4, 5 and
Daniela
S.
Rosa1, 4*
-
1
Federal University of São Paulo- UNIFESP, Departament of Immunology, Brazil
-
2
University of São Paulo School of Medicine, Brazil
-
3
University of São Paulo, Department of Parasitology, Brazil
-
4
Institute for Investigation in Immunology-INCT, Brazil
-
5
Heart Institute (INCOR), Brazil
An effective HIV vaccine is urgently needed and is still a scientific challenge. It is widely accepted that robust humoral and T cell responses are required for the control of virus transmission and disease progression. However, the induction of broadly neutralizing antibodies against the virus has proven hard to achieve. One of the most promising antigens is the envelope glycoprotein, but vaccine candidates based on the monomeric envelope protein gp120 failed to induce protection in efficacy trials. One strategy to overcome this caveat is the use of the stable envelope protein trimer gp140 that contains both gp120 and gp41 ectodomains.
Adjuvants are known to improve the immunogenicity of subunit vaccines, and in the last years several TLR and NOD ligands have entered clinical trials and proved their efficacy. They can also modulate the type of immune response induced by the antigen towards a specific profile (Th1, Th2, etc). For the present work, we used different adjuvant formulations (Poly I:C, CpG ODN, MPL, MDP, Imiquimod, Resiquimod) and analyzed their influence on the anti-gp140 antibody titers, IgG isotypes and germinal center formation after immunization in the presence of the gp140 trimer. Robust Env-specific antibody titers and germinal center formation developed after three doses of gp140 in the presence of different adjuvant formulations. The adjuvants MPL, Poly I:C and CpG ODN induced the highest humoral immune response. These observations have implications for gp140 subunit vaccine design and may be relevant for optimal responses in nonhuman and human primates.
Acknowledgements
This work was supported by the Brazilian National Research Council (CNPq) and São Paulo State Research Funding Agency (FAPESP),
Keywords:
Vaccine,
HIV vaccines,
HIV envelope protein gp140,
Adjuvants, Immunologic,
Humoral Immune Response
Conference:
15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013.
Presentation Type:
Abstract
Topic:
Translational immunology and immune intervention
Citation:
Apostólico
JD,
Boscardin
SB,
Yamamoto
MM,
Ribeiro
SP,
Ribeiro
R,
Kalil
J,
Cunha-Neto
E and
Rosa
DS
(2013). Influence of different adjuvant formulations in humoral responses after immunization with a HIV envelope glycoprotein trimer..
Front. Immunol.
Conference Abstract:
15th International Congress of Immunology (ICI).
doi: 10.3389/conf.fimmu.2013.02.00514
Copyright:
The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers.
They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.
The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.
Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.
For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.
Received:
22 May 2013;
Published Online:
22 Aug 2013.
*
Correspondence:
Prof. Daniela S Rosa, Federal University of São Paulo- UNIFESP, Departament of Immunology, São Paulo, São Paulo, 04023-062, Brazil, dsantororosa@gmail.com